The US Food and Drug Administration (FDA) announced on October 14, 2026 the Rare Disease Framework Initiative, an effort to rethink how medicines and biological products for rare diseases are developed and reviewed. The agency will hear feedback at a public meeting on October 28 at its White Oak campus in Silver Spring, Maryland.
The initiative aims to build a framework fitted to each disease, the needs of patients, the type of product and the evidence that can realistically be gathered from small patient populations, rather than applying one approach to every condition. It is set out in an FDA white paper titled "A New Framework for Rare Disease Review", which covers the whole path from early contact with developers before clinical trials to requirements after a product reaches the market.
The work is led by the FDA's Rare Disease Innovation Hub, together with the Office of the Commissioner, the Center for Drug Evaluation and Research and the Center for Biologics Evaluation and Research. The FDA lists six commitments: clearer and more predictable decisions, patient input at defined stages, more use of outside experts, shared resources and training, risk-based review of manufacturing and inspections, and wider use of advanced scientific and statistical methods.
The FDA notes that only about 5% of rare conditions have an FDA-approved treatment. About 30 million Americans live with a rare disease, according to the agency. Acting FDA Commissioner Kyle Diamantas said: "The FDA will fight hard for patients by building a more consistent, predictable, and innovative approach" to rare disease drug development. Amy Comstock Rick, director of the Rare Disease Innovation Hub, said: "This new framework will enhance consistency and predictability for both sponsors and for patients."
The Reagan-Udall Foundation for the FDA will run the October 28 meeting. After it, the agency plans sector-specific roundtables, requests for information and internal feedback sessions with its review staff. The input will inform possible new or revised guidance, regulatory changes, staff training and changes to how the agency is organized. The FDA has not set a public timeline for its first recommendations.
